相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Integrative Genomic Analyses of Sporadic Clear Cell Renal Cell Carcinoma Define Disease Subtypes and Potential New Therapeutic Targets
Vijay R. Dondeti et al.
CANCER RESEARCH (2012)
Single-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney Tumor
Xun Xu et al.
CELL (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model
J. S. P. Yuen et al.
BRITISH JOURNAL OF CANCER (2011)
The Mammalian Target of Rapamycin Pathway Is Widely Activated Without PTEN Deletion in Renal Cell Carcinoma Metastases
Tamer Abou Youssif et al.
CANCER (2011)
A Blueprint for Advancing Genetics-Based Cancer Therapy
William R. Sellers
CELL (2011)
Regulation of TFEB and V-ATPases by mTORC1
Samuel Pena-Llopis et al.
EMBO JOURNAL (2011)
Development and Characterization of Clinically Relevant Tumor Models From Patients With Renal Cell Carcinoma
Jose A. Karam et al.
EUROPEAN UROLOGY (2011)
Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients
Chiara Grisanzio et al.
JOURNAL OF PATHOLOGY (2011)
Interplay Between pVHL and mTORC1 Pathways in Clear-Cell Renal Cell Carcinoma
Blanka Kucejova et al.
MOLECULAR CANCER RESEARCH (2011)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al.
LANCET (2011)
Preclinical development of molecular-targeted agents for cancer
Alberto Ocana et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC
Toshinari Yamasaki et al.
NATURE REVIEWS UROLOGY (2011)
Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death
B. Kucejova et al.
ONCOGENE (2011)
Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Hypoxia-Inducible Factors and the Response to Hypoxic Stress
Amar J. Majmundar et al.
MOLECULAR CELL (2010)
Genome remodelling in a basal-like breast cancer metastasis and xenograft
Li Ding et al.
NATURE (2010)
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim et al.
NATURE (2010)
Anticancer drug development: the grand challenges
William N. Hait
NATURE REVIEWS DRUG DISCOVERY (2010)
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
Jeffrey J. Raizer et al.
NEURO-ONCOLOGY (2010)
Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays
Meng Chen et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors
Michael L. Nickerson et al.
CLINICAL CANCER RESEARCH (2008)
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics
Ahmad Awada et al.
EUROPEAN JOURNAL OF CANCER (2008)
Sirolimus in metatastic renal cell carcinoma
James Brugarolas et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
The RSK family of kinases: emerging roles in cellular signalling
Rana Anjum et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer
William G. Kaelin
NATURE REVIEWS CANCER (2008)
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer
Ronald M. Bukowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis
R. M. Bukowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic relevance of the mTOR pathway in renal cell carcinoma - Implications for molecular patient selection for targeted therapy
Allan J. Pantuck et al.
CANCER (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Murine models to evaluate novel and conventional therapeutic strategies for cancer
James E. Talmadge et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Activation of the mTOR signaling pathway in renal clear cell carcinoma
Victoria A. Robb et al.
JOURNAL OF UROLOGY (2007)
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines
Jeongwu Lee et al.
CANCER CELL (2006)
Contributions of human tumor xenografts to anticancer drug development
EA Sausville et al.
CANCER RESEARCH (2006)
Endothelial/pericyte interactions
A Armulik et al.
CIRCULATION RESEARCH (2005)
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
S Trudel et al.
BLOOD (2005)
Population pharmacokinetics of CCI-779: Correlations to safety and pharmacogenomic responses in patients with advanced renal cancer
JP Boni et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
N Ferrara et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development
JK Peterson et al.
EUROPEAN JOURNAL OF CANCER (2004)
Clonogenic assay with established human tumour xenografts:: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery
HH Fiebig et al.
EUROPEAN JOURNAL OF CANCER (2004)
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
MB Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor
AR Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
E Raymond et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Circular binary segmentation for the analysis of array-based DNA copy number data
AB Olshen et al.
BIOSTATISTICS (2004)
TSC2 regulates VEGF through mTOR-dependent and -independent pathways
JB Brugarolas et al.
CANCER CELL (2003)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
